
Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global GLP-1 Targeted Peptide Weight Loss Drugs market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Targeted Peptide Weight Loss Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Targeted Peptide Weight Loss Drugs.
The GLP-1 Targeted Peptide Weight Loss Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GLP-1 Targeted Peptide Weight Loss Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Company
Chugai Pharmaceutical
Benemae Pharmaceutical
Qilu Pharmaceutical
Jiuyuan Gene Engineering
Huadong Medicine
Zealand Pharma
The General Hospital Corp
Sanofi-Aventis
QuiaPEG Pharmaceuticals Ab
Orbis Biosciences
Novo Nordisk
Nano Precision Medical
Nanexa AB
Lexaria Bioscience
iX Biopharma
Intarcia Therapeutics
HIKMA PHARMS
Eli Lilly
Baxter Pharmaceutical
Astra Zeneca
Amylin Pharmaceuticals
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type
Oral
Injection
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application
Hospital
Clinic
Others
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global GLP-1 Targeted Peptide Weight Loss Drugs market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of GLP-1 Targeted Peptide Weight Loss Drugs include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Targeted Peptide Weight Loss Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Targeted Peptide Weight Loss Drugs.
The GLP-1 Targeted Peptide Weight Loss Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GLP-1 Targeted Peptide Weight Loss Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Company
Chugai Pharmaceutical
Benemae Pharmaceutical
Qilu Pharmaceutical
Jiuyuan Gene Engineering
Huadong Medicine
Zealand Pharma
The General Hospital Corp
Sanofi-Aventis
QuiaPEG Pharmaceuticals Ab
Orbis Biosciences
Novo Nordisk
Nano Precision Medical
Nanexa AB
Lexaria Bioscience
iX Biopharma
Intarcia Therapeutics
HIKMA PHARMS
Eli Lilly
Baxter Pharmaceutical
Astra Zeneca
Amylin Pharmaceuticals
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type
Oral
Injection
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application
Hospital
Clinic
Others
GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
123 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Estimates and Forecasts (2020-2031)
- 1.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Estimates and Forecasts (2020-2031)
- 1.3 GLP-1 Targeted Peptide Weight Loss Drugs Market by Type
- 1.3.1 Oral
- 1.3.2 Injection
- 1.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Type
- 1.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Overview by Type (2020-2031)
- 1.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Historic Market Size Review by Type (2020-2025)
- 1.4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Forecasted Market Size by Type (2026-2031)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2020-2025)
- 1.5.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2020-2025)
- 1.5.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2020-2025)
- 1.5.4 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2020-2025)
- 1.5.5 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Type (2020-2025)
- 2 Global Market Dynamics
- 2.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
- 2.2 GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers
- 2.3 GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges
- 2.4 GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints
- 3 Market Competitive Landscape by Company
- 3.1 Global Top Players by GLP-1 Targeted Peptide Weight Loss Drugs Revenue (2020-2025)
- 3.2 Global Top Players by GLP-1 Targeted Peptide Weight Loss Drugs Sales (2020-2025)
- 3.3 Global Top Players by GLP-1 Targeted Peptide Weight Loss Drugs Price (2020-2025)
- 3.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Industry Company Ranking, 2023 VS 2024 VS 2025
- 3.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Major Company Production Sites & Headquarters
- 3.6 Global GLP-1 Targeted Peptide Weight Loss Drugs Company, Product Type & Application
- 3.7 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 GLP-1 Targeted Peptide Weight Loss Drugs Players Market Share by Revenue in 2024
- 3.8.3 2023 GLP-1 Targeted Peptide Weight Loss Drugs Tier 1, Tier 2, and Tier 3
- 4 GLP-1 Targeted Peptide Weight Loss Drugs Regional Status and Outlook
- 4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size and CAGR by Region: 2020 VS 2024 VS 2031
- 4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Historic Market Size by Region
- 4.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Volume by Region (2020-2025)
- 4.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Value by Region (2020-2025)
- 4.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (Volume & Value), Price and Gross Margin (2020-2025)
- 4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Forecasted Market Size by Region
- 4.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Volume by Region (2026-2031)
- 4.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales in Value by Region (2026-2031)
- 4.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (Volume & Value), Price and Gross Margin (2026-2031)
- 5 GLP-1 Targeted Peptide Weight Loss Drugs by Application
- 5.1 GLP-1 Targeted Peptide Weight Loss Drugs Market by Application
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Application
- 5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Size Overview by Application (2020-2031)
- 5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Historic Market Size Review by Application (2020-2025)
- 5.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Forecasted Market Size by Application (2026-2031)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2020-2025)
- 5.3.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2020-2025)
- 5.3.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2020-2025)
- 5.3.4 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2020-2025)
- 5.3.5 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Breakdown by Application (2020-2025)
- 6 Company Profiles
- 6.1 Chugai Pharmaceutical
- 6.1.1 Chugai Pharmaceutical Comapny Information
- 6.1.2 Chugai Pharmaceutical Business Overview
- 6.1.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.1.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.1.5 Chugai Pharmaceutical Recent Developments
- 6.2 Benemae Pharmaceutical
- 6.2.1 Benemae Pharmaceutical Comapny Information
- 6.2.2 Benemae Pharmaceutical Business Overview
- 6.2.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.2.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.2.5 Benemae Pharmaceutical Recent Developments
- 6.3 Qilu Pharmaceutical
- 6.3.1 Qilu Pharmaceutical Comapny Information
- 6.3.2 Qilu Pharmaceutical Business Overview
- 6.3.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.3.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.3.5 Qilu Pharmaceutical Recent Developments
- 6.4 Jiuyuan Gene Engineering
- 6.4.1 Jiuyuan Gene Engineering Comapny Information
- 6.4.2 Jiuyuan Gene Engineering Business Overview
- 6.4.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.4.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.4.5 Jiuyuan Gene Engineering Recent Developments
- 6.5 Huadong Medicine
- 6.5.1 Huadong Medicine Comapny Information
- 6.5.2 Huadong Medicine Business Overview
- 6.5.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.5.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.5.5 Huadong Medicine Recent Developments
- 6.6 Zealand Pharma
- 6.6.1 Zealand Pharma Comapny Information
- 6.6.2 Zealand Pharma Business Overview
- 6.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.6.5 Zealand Pharma Recent Developments
- 6.7 The General Hospital Corp
- 6.7.1 The General Hospital Corp Comapny Information
- 6.7.2 The General Hospital Corp Business Overview
- 6.7.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.7.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.7.5 The General Hospital Corp Recent Developments
- 6.8 Sanofi-Aventis
- 6.8.1 Sanofi-Aventis Comapny Information
- 6.8.2 Sanofi-Aventis Business Overview
- 6.8.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.8.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.8.5 Sanofi-Aventis Recent Developments
- 6.9 QuiaPEG Pharmaceuticals Ab
- 6.9.1 QuiaPEG Pharmaceuticals Ab Comapny Information
- 6.9.2 QuiaPEG Pharmaceuticals Ab Business Overview
- 6.9.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.9.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.9.5 QuiaPEG Pharmaceuticals Ab Recent Developments
- 6.10 Orbis Biosciences
- 6.10.1 Orbis Biosciences Comapny Information
- 6.10.2 Orbis Biosciences Business Overview
- 6.10.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.10.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.10.5 Orbis Biosciences Recent Developments
- 6.11 Novo Nordisk
- 6.11.1 Novo Nordisk Comapny Information
- 6.11.2 Novo Nordisk Business Overview
- 6.11.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.11.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.11.5 Novo Nordisk Recent Developments
- 6.12 Nano Precision Medical
- 6.12.1 Nano Precision Medical Comapny Information
- 6.12.2 Nano Precision Medical Business Overview
- 6.12.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.12.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.12.5 Nano Precision Medical Recent Developments
- 6.13 Nanexa AB
- 6.13.1 Nanexa AB Comapny Information
- 6.13.2 Nanexa AB Business Overview
- 6.13.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.13.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.13.5 Nanexa AB Recent Developments
- 6.14 Lexaria Bioscience
- 6.14.1 Lexaria Bioscience Comapny Information
- 6.14.2 Lexaria Bioscience Business Overview
- 6.14.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.14.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.14.5 Lexaria Bioscience Recent Developments
- 6.15 iX Biopharma
- 6.15.1 iX Biopharma Comapny Information
- 6.15.2 iX Biopharma Business Overview
- 6.15.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.15.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.15.5 iX Biopharma Recent Developments
- 6.16 Intarcia Therapeutics
- 6.16.1 Intarcia Therapeutics Comapny Information
- 6.16.2 Intarcia Therapeutics Business Overview
- 6.16.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.16.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.16.5 Intarcia Therapeutics Recent Developments
- 6.17 HIKMA PHARMS
- 6.17.1 HIKMA PHARMS Comapny Information
- 6.17.2 HIKMA PHARMS Business Overview
- 6.17.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.17.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.17.5 HIKMA PHARMS Recent Developments
- 6.18 Eli Lilly
- 6.18.1 Eli Lilly Comapny Information
- 6.18.2 Eli Lilly Business Overview
- 6.18.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.18.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.18.5 Eli Lilly Recent Developments
- 6.19 Baxter Pharmaceutical
- 6.19.1 Baxter Pharmaceutical Comapny Information
- 6.19.2 Baxter Pharmaceutical Business Overview
- 6.19.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.19.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.19.5 Baxter Pharmaceutical Recent Developments
- 6.20 Astra Zeneca
- 6.20.1 Astra Zeneca Comapny Information
- 6.20.2 Astra Zeneca Business Overview
- 6.20.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.20.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.20.5 Astra Zeneca Recent Developments
- 6.21 Amylin Pharmaceuticals
- 6.21.1 Amylin Pharmaceuticals Comapny Information
- 6.21.2 Amylin Pharmaceuticals Business Overview
- 6.21.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Revenue and Gross Margin (2020-2025)
- 6.21.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
- 6.21.5 Amylin Pharmaceuticals Recent Developments
- 7 North America by Country
- 7.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
- 7.1.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.1.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025)
- 7.1.3 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2026-2031)
- 7.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
- 7.2.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2020-2025)
- 7.2.3 North America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2026-2031)
- 8 Europe by Country
- 8.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
- 8.1.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.1.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025)
- 8.1.3 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2026-2031)
- 8.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
- 8.2.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2020-2025)
- 8.2.3 Europe GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific by Country
- 9.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
- 9.1.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.1.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025)
- 9.1.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2026-2031)
- 9.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
- 9.2.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2020-2025)
- 9.2.3 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2026-2031)
- 10 South America by Country
- 10.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
- 10.1.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.1.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025)
- 10.1.3 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2026-2031)
- 10.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
- 10.2.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2020-2025)
- 10.2.3 South America GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2026-2031)
- 11 Middle East and Africa by Country
- 11.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country
- 11.1.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.1.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2020-2025)
- 11.1.3 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Forecast by Country (2026-2031)
- 11.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country
- 11.2.1 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2.2 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size by Country (2020-2025)
- 11.2.3 Middle East and Africa GLP-1 Targeted Peptide Weight Loss Drugs Market Size Forecast by Country (2026-2031)
- 12 Value Chain and Sales Channels Analysis
- 12.1 GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Analysis
- 12.1.1 GLP-1 Targeted Peptide Weight Loss Drugs Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 GLP-1 Targeted Peptide Weight Loss Drugs Production Mode & Process
- 12.2 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
- 12.2.3 GLP-1 Targeted Peptide Weight Loss Drugs Customers
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.